Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Dec 22, 2023 10:58am
122 Views
Post# 35797691

RE:RE:RE:ADC targeting SORT1

RE:RE:RE:ADC targeting SORT1

They did not chose PDC over ADC.They purchased Katana 5-6 years ago which had been trying to find a Buyer for more than a year and was not able to get a deal with any pharnas/biotechs involved in oncology...So THTX was apparently the only suitor .... no expertise in oncology .no corporate stucture to support going into R&D and no financial means to see this novel platform thru ....Of course at the time of the purchase it was getting hot in the kitchen with Trogarzo sales failing miserably ....Hoping for positive results of course but with low expectations unless a real oncology compagny decides to partner  with THTX .....
 

 

Mannequin wrote: But a PDC should be able to work its way in and release payload better than ADC. There's reasons they chose PDC. 

 

<< Previous
Bullboard Posts
Next >>